Managers

Risalto Health inks $7 mln

Risalto Health, a digital health services company focused on musculoskeletal care, has raised $7 million in funding. The investor was Health Catalyst Capital Management.

Avidity Biosciences fetches $100 mln Series C

La Jolla, California-based Avidity Biosciences, a biotechnology company, has secured $100 million in Series C financing. RTW Investments led the round. In addition to the funding, Dr. Roderick T. Wong, a managing partner of RTW Investments, will join Avidity Biosciences’ board of directors.

Sera Prognostics lands $36 mln Series D

Salt Lake City-based Sera Prognostics Inc, a health diagnostics company, has secured $36 million in Series D funding. Blue Ox Healthcare Partners led the round with participation from other investors that included Domain Associates, InterWest Partners, Laboratory Corporation of America Holdings, Catalyst Health Ventures and Chione Ltd.

VC-backed OODA Health adds KKR senior adviser to board

San Francisco-based OODA Health has named Diego Piacentini to its board of directors.

Actuate Therapeutics gathers $6.5 mln

Fort Worth, Texas-based Actuate Therapeutics Inc, a clinical stage biopharmaceutical company, has raised $6.5 million in financing. Bios Partners led the round with participation from other investors that included Kairos Ventures and DEFTA Partners.

Apervita fetches $22 mln

Chicago and Boston-based Apervita, a platform for value-based collaboration in healthcare, has secured $22 million in funding. The investors included Optum Ventures, Pritzker Group Venture Capital, Baird Capital, Math Ventures and Levy Family Partners.

In U.K. and Israel, Reimagine's GPs are growing entertainment tech

Co-founders Eze Vidra and Kevin Baxpehler plan to use the firm's first fund to build up Israeli entertainment technology startups.

Seed investor Angular Ventures raises $41 mln for European Israeli startups

The firm, headquartered in London, raised $16 million more than the initial target for its first fund.

89Bio debuts IPO

San Francisco and Israel-based 89Bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis and other liver and metabolic disorders, has raised about $84.9 million for its IPO after pricing its over 5.3 million shares at $16 per share. The stock began trading November 11, 2019 on the NASDAQ under the ticker symbol "ETNB." BofA Securities, SVB Leerink and RBC Capital Markets are the lead underwriters. 89Bio's pre-IPO backers include OrbiMed Israel, OrbiMed US, Longitude Capital, RA Capital Management and Pontifax.

Event marketing and management are ripe for disruption